173 related articles for article (PubMed ID: 23635096)
1. Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.
Suzuki H; Sakamoto M; Hayashi T; Iuchi H; Ohashi K; Isaka T; Sakamoto N; Kayama Y; Tojo K; Yoshimura M; Utsunomiya K
Cardiovasc Diabetol; 2013 May; 12():71. PubMed ID: 23635096
[TBL] [Abstract][Full Text] [Related]
2. Effects of candesartan in hypertensive patients with type 2 diabetes mellitus on inflammatory parameters and their relationship to pulse pressure.
Sakamoto M; Suzuki H; Hayashi T; Iuchi H; Isaka T; Sakamoto N; Kayama Y; Tojo K; Yoshimura M; Utsunomiya K
Cardiovasc Diabetol; 2012 Oct; 11():118. PubMed ID: 23034088
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
4. Effects of candesartan cilexetil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus.
Rosei EA; Rizzoni D; Muiesan ML; Sleiman I; Salvetti M; Monteduro C; Porteri E;
J Hypertens; 2005 Feb; 23(2):435-44. PubMed ID: 15662233
[TBL] [Abstract][Full Text] [Related]
5. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
Arao T; Okada Y; Mori H; Nishida K; Tanaka Y
Endocr J; 2013; 60(5):563-70. PubMed ID: 23303198
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; Fogari E; D'Angelo A; Cicero AF
Hypertens Res; 2010 Aug; 33(8):790-5. PubMed ID: 20505674
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers.
Takase H; Nakazawa A; Yamashita S; Toriyama T; Sato K; Ueda R; Dohi Y
Metabolism; 2007 Apr; 56(4):559-64. PubMed ID: 17379017
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
[TBL] [Abstract][Full Text] [Related]
10. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
Daikuhara H; Kikuchi F; Ishida T
Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
[TBL] [Abstract][Full Text] [Related]
11. Comparison between single and combined treatment with candesartan and pioglitazone following transient focal ischemia in rat brain.
Schmerbach K; Schefe JH; Krikov M; Müller S; Villringer A; Kintscher U; Unger T; Thoene-Reineke C
Brain Res; 2008 May; 1208():225-33. PubMed ID: 18378216
[TBL] [Abstract][Full Text] [Related]
12. Role of angiotensin II in plasma PAI-1 changes induced by imidapril or candesartan in hypertensive patients with metabolic syndrome.
Fogari R; Zoppi A; Mugellini A; Maffioli P; Lazzari P; Derosa G
Hypertens Res; 2011 Dec; 34(12):1321-6. PubMed ID: 21814211
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin II type-I receptor blocker, candesartan, improves brachial-ankle pulse wave velocity independent of its blood pressure lowering effects in type 2 diabetes patients.
Ishii H; Tsukada T; Yoshida M
Intern Med; 2008; 47(23):2013-8. PubMed ID: 19043252
[TBL] [Abstract][Full Text] [Related]
14. Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.
Yajima K; Shimada A; Hirose H; Oikawa Y; Yamada S; Meguro S; Irie J; Irie S
Clin Drug Investig; 2009; 29(12):811-9. PubMed ID: 19888787
[TBL] [Abstract][Full Text] [Related]
15. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin.
Derosa G; Fogari E; Cicero AF; D'Angelo A; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Gravina A; Ferrari I; Fogari R
Hypertens Res; 2007 May; 30(5):387-94. PubMed ID: 17587750
[TBL] [Abstract][Full Text] [Related]
17. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
[TBL] [Abstract][Full Text] [Related]
18. Effect of combination therapy of benidipine hydrochloride and candesartan cilexetil on serum lipid metabolism and blood pressure in elderly hypertensive patients with type 2 diabetes mellitus.
Sasaki H; Kanai S; Oyama T; Miyashita Y; Yamamura S; Shirai K
J Atheroscler Thromb; 2006 Jun; 13(3):149-57. PubMed ID: 16835470
[TBL] [Abstract][Full Text] [Related]
19. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
20. The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
Esteghamati A; Azizi R; Ebadi M; Noshad S; Mousavizadeh M; Afarideh M; Nakhjavani M
Exp Clin Endocrinol Diabetes; 2015 May; 123(5):289-95. PubMed ID: 25607338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]